--- title: "Context Therapeutics (CNTX) news: reverse split and lawsuit" url: "https://aibio.space/companies/context-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CNTX reverse split and lawsuit news: Context Therapeutics gets Nasdaq extension to February 23, 2026 on minimum bid price rule. Context Therapeutics Inc." --- CNTX Context Therapeutics Inc. NASDAQ · United States # Context Therapeutics (CNTX) news CNTX reverse split and lawsuit news Legal · 2026-08-05 ## [Context Therapeutics closes Delaware suit over three-year director terms; $850,000 fee paid](https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/) The Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000. ## Latest Context Therapeutics news 1. 2025-09-02 Listings [Context Therapeutics gets Nasdaq extension to February 23, 2026 on minimum bid price rule](https://aibio.space/news/context-therapeutics-gets-nasdaq-extension-february-23-2026-minimum/) Nasdaq gave Context Therapeutics until February 23, 2026 to regain compliance with the $1.00 minimum bid price rule. The company says it may need a reverse stock split and cannot promise it will regain compliance. 2. 2025-09-02 Listings [Context Therapeutics gets 180 more days from Nasdaq to meet $1.00 bid price rule](https://aibio.space/news/context-therapeutics-gets-180-more-days-nasdaq-meet-1-00-bid-price/) The new deadline is February 23, 2026. The company says a reverse stock split is an option if needed, and it gives no assurance it will regain compliance by then. 3. 2024-12-23 Financings [Context Therapeutics sells 14,705,882 shares for about $15 million to MPM BioImpact](https://aibio.space/news/context-therapeutics-sells-14-705-882-shares-about-15-million-mpm/) The shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024. ## Context Therapeutics at a glance - **Ticker**: CNTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $43.0 million ### Related companies - [Retension Pharmaceuticals](https://aibio.space/companies/retension-pharmaceuticals/) NASDAQ: RTSN - [Vericel](https://aibio.space/companies/vericel/) NASDAQ: VCEL - [RegeneRx Biopharmaceuticals](https://aibio.space/companies/regenerx-biopharmaceuticals/) OTC: RGRX - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) NASDAQ: SKYE - [NRX Pharmaceuticals](https://aibio.space/companies/nrx-pharmaceuticals/) NASDAQ: NRXP - [Ocugen](https://aibio.space/companies/ocugen/) NASDAQ: OCGN - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) NASDAQ: ALNY - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN ### Also on NASDAQ - [Elicio Therapeutics](https://aibio.space/companies/elicio-therapeutics/) ELTX - [NewcelX](https://aibio.space/companies/newcelx/) NCEL - [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) SLGL - [TuHURA Biosciences](https://aibio.space/companies/tuhura-biosciences/) HURA - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) TGTX - [HeartBeam](https://aibio.space/companies/heartbeam/) BEATW ## What Context Therapeutics does Context Therapeutics is a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors. Its pipeline includes CTIM-76, a CLDN6 x CD3 TCE that the company says is highly selective for CLDN6 over related claudins and may reach tumors with low, medium or high CLDN6 expression. CTIM-76 is in a Phase 1 dose escalation and expansion trial in patients with CLDN6-positive gynecologic and testicular cancers, with the first patient dosed in January 2025. CT-95, a mesothelin x CD3 TCE, is also in Phase 1, with the first patient dosed in April 2025. CT-202, a Nectin-4 x CD3 pH-dependent TCE designed to be preferentially active within the tumor microenvironment, had its first-in-human application submitted to an Australian ethics committee in March 2026. The company expects to dose the first patient in the CT-202 Phase 1 trial in the third quarter of 2026. | Product or program | What it is | Stage | |---|---|---| | CTIM-76 | CLDN6 x CD3 T cell engaging bispecific antibody for solid tumors | Phase 1; first patient dosed January 2025 | | CT-95 | Mesothelin x CD3 T cell engaging bispecific antibody | Phase 1; first patient dosed April 2025 | | CT-202 | pH-dependent Nectin-4 x CD3 T cell engaging bispecific antibody | first patient dosing expected in the third quarter of 2026 | Summarised from the company's [10-K filed Mar 23, 2026](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/cntx-20251231.htm). ## Context Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$31.9 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/) | [$22.7 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/) | | Net income (loss) | [-$36.1 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/) | [-$26.7 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/) | | Cash from operations | [-$26.4 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/) | [-$14.6 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/) | | Cash and equivalents | [$66.0 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026053347/) | [$94.4 million](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $43.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Context Therapeutics Did Context Therapeutics do a reverse stock split? Our latest story on this, dated Sep 2, 2025: "Context Therapeutics gets Nasdaq extension to February 23, 2026 on minimum bid price rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/context-therapeutics-gets-nasdaq-extension-february-23-2026-minimum/). Is Context Therapeutics involved in a lawsuit? Our latest story on this, dated Aug 5, 2026: "Context Therapeutics closes Delaware suit over three-year director terms; $850,000 fee paid". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/). What is the ticker symbol of Context Therapeutics? Context Therapeutics Inc. trades under the ticker CNTX on NASDAQ. Where is Context Therapeutics listed? Context Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:6K9; LS:A3CWBU; LSX:A3CWBU. What is the SEC CIK of Context Therapeutics? The SEC Central Index Key (CIK) for Context Therapeutics Inc. is 1842952. Its filings are on SEC EDGAR. How many shares does Context Therapeutics have outstanding? 91,879,177 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Context Therapeutics listed under? Our directory records Context Therapeutics Inc. under United States. What does Context Therapeutics do? Our directory classifies Context Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Context Therapeutics? The ISIN recorded for Context Therapeutics Inc. is US21077P1084. Does aibio.space cover Context Therapeutics? aibio.space lists Context Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Context Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Context Therapeutics develop? Context Therapeutics is a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors. Its pipeline includes CTIM-76, a CLDN6 x CD3 TCE that the company says is highly selective for CLDN6 over related claudins and may reach tumors with low, medium or high CLDN6 expression. What is CTIM-76 from Context Therapeutics? CTIM-76: CLDN6 x CD3 T cell engaging bispecific antibody for solid tumors Stage: Phase 1; first patient dosed January 2025. What is CT-95 from Context Therapeutics? CT-95: Mesothelin x CD3 T cell engaging bispecific antibody Stage: Phase 1; first patient dosed April 2025. Is Context Therapeutics profitable? Context Therapeutics Inc. reported a net loss of $36.1 million for the fiscal year ended Dec 31, 2025, and used $26.4 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Context Therapeutics Members talk about Context Therapeutics (CNTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Context Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000162828026051399/cntx-20260729.htm) 2. 2026-06-26 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm) 3. 2026-03-23 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1842952/000162828026020498/cntx-20251231.htm) 4. 2026-02-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000162828026012813/cntx-20260224.htm) 5. 2025-10-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1842952/000162828025046256/contexttherapeutics424b5oc.htm) 6. 2025-10-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000162828025045513/cntx-20251017.htm) 7. 2025-09-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000085/cntx-20250828.htm) 8. 2025-06-12 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000072/cntx-20250612.htm) 9. 2025-04-15 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000042/cntx-20250415.htm) 10. 2025-04-04 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000034/cntx-20250404.htm) 11. 2025-03-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000028/cntx-20241231.htm) 12. 2025-02-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000024/cntx-20250227.htm) 13. 2024-12-23 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1842952/000184295224000087/cntx-20241223.htm) 14. 2024-12-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1842952/000162828024049568/contexttherapeutics-424b5p.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CNTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-CNTX/). ## SEC filings and registration - **SEC name**: Context Therapeutics Inc. - **CIK**: 1842952 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CNTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2001 MARKET STREET, PHILADELPHIA, PA, 19103 - **Phone**: 267-225-7416 - **Shares outstanding**: 91,879,177 as of 2026-08-03 (10-Q filed 2026-08-05) - **Former names**: Context Therapeutics LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026053378/cntx-20260805.htm) filed 2026-08-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1842952/000162828026053347/cntx-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026051399/cntx-20260729.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/cntx-20260615.htm) filed 2026-06-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026035793/cntx-20260514.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1842952/000162828026031267/cntx-20260331.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1842952/000162828026029323/cntx-20260430.htm) filed 2026-05-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001842952), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Context Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CNTX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Context Therapeutics Inc. - **Ticker**: CNTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US21077P1084 - **Other listed symbols**: GETTEX:6K9; LS:A3CWBU; LSX:A3CWBU - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CNTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/context-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Context Therapeutics (CNTX) news: reverse split and lawsuit", 2026-10-31, https://aibio.space/companies/context-therapeutics/